Cite
Lobo J, Leão R, Gillis AJM, et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol. 2020;4(3):483-491doi: 10.1016/j.euo.2020.11.004.
Lobo, J., Leão, R., Gillis, A. J. M., van den Berg, A., Anson-Cartwright, L., Atenafu, E. G., Kuhathaas, K., Chung, P., Hansen, A., Bedard, P. L., Jewett, M. A. S., Warde, P., O'Malley, M., Sweet, J., Looijenga, L. H. J., & Hamilton, R. J. (2021). Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. European urology oncology, 4(3), 483-491. https://doi.org/10.1016/j.euo.2020.11.004
Lobo, João, et al. "Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer." European urology oncology vol. 4,3 (2021): 483-491. doi: https://doi.org/10.1016/j.euo.2020.11.004
Lobo J, Leão R, Gillis AJM, van den Berg A, Anson-Cartwright L, Atenafu EG, Kuhathaas K, Chung P, Hansen A, Bedard PL, Jewett MAS, Warde P, O'Malley M, Sweet J, Looijenga LHJ, Hamilton RJ. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol. 2021 Jun;4(3):483-491. doi: 10.1016/j.euo.2020.11.004. Epub 2020 Dec 04. PMID: 33288479.
Copy
Download .nbib